File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1002/biot.201900456
- Scopus: eid_2-s2.0-85081737216
- PMID: 32107862
- WOS: WOS:000559735900011
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Synthesis of Injectable Shear-Thinning Biomaterials of Various Compositions of Gelatin and Synthetic Silicate Nanoplatelet
Title | Synthesis of Injectable Shear-Thinning Biomaterials of Various Compositions of Gelatin and Synthetic Silicate Nanoplatelet |
---|---|
Authors | |
Keywords | injectability laponite rheology shear-thinning biomaterial gelatin |
Issue Date | 2020 |
Citation | Biotechnology Journal, 2020, v. 15, n. 8, article no. 1900456 How to Cite? |
Abstract | © 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim Injectable shear-thinning biomaterials (iSTBs) have great potential for in situ tissue regeneration through minimally invasive therapeutics. Previously, an iSTB was developed by combining gelatin with synthetic silicate nanoplatelets (SNPs) for potential application to hemostasis and endovascular embolization. Hence, iSTBs are synthesized by varying compositions of gelatin and SNPs to navigate their material, mechanical, rheological, and bioactive properties. All compositions (each component percentage; 1.5–4.5%/total solid ranges; 3–9%) tested are injectable through both 5 Fr general catheter and 2.4 Fr microcatheter by manual pressure. In the results, an increase in gelatin contents causes decrease in swellability, increase in freeze-dried hydrogel scaffold porosity, increase in degradability and injection force during iSTB fabrication. Meanwhile, the amount of SNPs in composite hydrogels is mainly required to decrease degradability and increase shear thinning properties of iSTB. Finally, in vitro and in vivo biocompatibility tests show that the 1.5–4.5% range gelatin–SNP iSTBs are not toxic to the cells and animals. All results demonstrate that the iSTB can be modulated with specific properties for unmet clinical needs. Understanding of mechanical and biological consequences of the changing gelatin–SNP ratios through this study will shed light on the biomedical applications of iSTB on specific diseases. |
Persistent Identifier | http://hdl.handle.net/10722/295421 |
ISSN | 2023 Impact Factor: 3.2 2023 SCImago Journal Rankings: 0.908 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Xue, Chengbin | - |
dc.contributor.author | Xie, Huifang | - |
dc.contributor.author | Eichenbaum, James | - |
dc.contributor.author | Chen, Yi | - |
dc.contributor.author | Wang, Yonggang | - |
dc.contributor.author | van den Dolder, Floor W. | - |
dc.contributor.author | Lee, Junmin | - |
dc.contributor.author | Lee, Kang Ju | - |
dc.contributor.author | Zhang, Shiming | - |
dc.contributor.author | Sun, Wujin | - |
dc.contributor.author | Sheikhi, Amir | - |
dc.contributor.author | Ahadian, Samad | - |
dc.contributor.author | Ashammakhi, Nureddin | - |
dc.contributor.author | Dokmeci, Mehmet R. | - |
dc.contributor.author | Kim, Han Jun | - |
dc.contributor.author | Khademhosseini, Ali | - |
dc.date.accessioned | 2021-01-18T15:46:50Z | - |
dc.date.available | 2021-01-18T15:46:50Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Biotechnology Journal, 2020, v. 15, n. 8, article no. 1900456 | - |
dc.identifier.issn | 1860-6768 | - |
dc.identifier.uri | http://hdl.handle.net/10722/295421 | - |
dc.description.abstract | © 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim Injectable shear-thinning biomaterials (iSTBs) have great potential for in situ tissue regeneration through minimally invasive therapeutics. Previously, an iSTB was developed by combining gelatin with synthetic silicate nanoplatelets (SNPs) for potential application to hemostasis and endovascular embolization. Hence, iSTBs are synthesized by varying compositions of gelatin and SNPs to navigate their material, mechanical, rheological, and bioactive properties. All compositions (each component percentage; 1.5–4.5%/total solid ranges; 3–9%) tested are injectable through both 5 Fr general catheter and 2.4 Fr microcatheter by manual pressure. In the results, an increase in gelatin contents causes decrease in swellability, increase in freeze-dried hydrogel scaffold porosity, increase in degradability and injection force during iSTB fabrication. Meanwhile, the amount of SNPs in composite hydrogels is mainly required to decrease degradability and increase shear thinning properties of iSTB. Finally, in vitro and in vivo biocompatibility tests show that the 1.5–4.5% range gelatin–SNP iSTBs are not toxic to the cells and animals. All results demonstrate that the iSTB can be modulated with specific properties for unmet clinical needs. Understanding of mechanical and biological consequences of the changing gelatin–SNP ratios through this study will shed light on the biomedical applications of iSTB on specific diseases. | - |
dc.language | eng | - |
dc.relation.ispartof | Biotechnology Journal | - |
dc.subject | injectability | - |
dc.subject | laponite | - |
dc.subject | rheology | - |
dc.subject | shear-thinning biomaterial | - |
dc.subject | gelatin | - |
dc.title | Synthesis of Injectable Shear-Thinning Biomaterials of Various Compositions of Gelatin and Synthetic Silicate Nanoplatelet | - |
dc.type | Article | - |
dc.description.nature | link_to_OA_fulltext | - |
dc.identifier.doi | 10.1002/biot.201900456 | - |
dc.identifier.pmid | 32107862 | - |
dc.identifier.pmcid | PMC7415533 | - |
dc.identifier.scopus | eid_2-s2.0-85081737216 | - |
dc.identifier.volume | 15 | - |
dc.identifier.issue | 8 | - |
dc.identifier.spage | article no. 1900456 | - |
dc.identifier.epage | article no. 1900456 | - |
dc.identifier.eissn | 1860-7314 | - |
dc.identifier.isi | WOS:000559735900011 | - |
dc.identifier.issnl | 1860-6768 | - |